This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Fludase

NexBio, Inc.

Drug Names(s): DAS181

Description: Fludase (DAS181) is a dry powder that is administered via oral inhalation. Fludase is a recombinant fusion protein that inactivates viral receptors on the cells of the human respiratory tract, thereby preventing influenza and other viruses such as parainfluenza from both infecting the human body and amplifying in already-infected individuals. Sialic acids on the surface of cells lining the human respiratory tract act as the host cell receptors for all influenza and parainfluenza viruses. Fludase works by cleaving the sialic acid on the airway epithelium, therefore preventing viral entry into cells.

DAS181 is a bifunctional fusion protein comprised of a sialidase linked to a polycationic sequence derived from human amphiregulin (hAR) that allows the molecule to target the sialidase enzymatic activity to negatively charged glycosaminoglycans, such as sialic acid.


Fludase News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug